The Roles of TGFβ in the Tumour Microenvironment

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2013 Oct 18

PMID 24132110

Citations 517

Authors

Michael Pickup

Sergey Novitskiy

Harold L Moses

Affiliations

Soon will be listed here.

Abstract

The influence of the microenvironment on tumour progression is becoming clearer. In this Review we address the role of an essential signalling pathway, that of transforming growth factor-β, in the regulation of components of the tumour microenvironment and how this contributes to tumour progression.

Citing Articles

Lymphatic system is the mainstream for breast cancer dissemination and metastasis revealed by single-cell lineage tracing.

Miao K, Zhang A, Yang X, Zhang Y, Lin A, Wang L Mol Cancer. 2025; 24(1):75.

PMID: 40075470 PMC: 11899007. DOI: 10.1186/s12943-025-02279-w.

Tumor-derived colorectal cancer organoids induce a unique Treg cell population by directing CD4 T cell differentiation.

Revilla S, Frederiks C, Prekovic S, Mocholi E, Kranenburg O, Coffer P iScience. 2025; 28(2):111827.

PMID: 39995881 PMC: 11848486. DOI: 10.1016/j.isci.2025.111827.

Cell Homing Strategies in Regenerative Endodontic Therapy.

Kim D, Kim S Cells. 2025; 14(3).

PMID: 39936992 PMC: 11817319. DOI: 10.3390/cells14030201.

Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity.

Ito Y, Kasuya H, Kataoka M, Nakamura N, Yoshikawa T, Nakashima T J Immunother Cancer. 2025; 13(1).

PMID: 39864848 PMC: 11784344. DOI: 10.1136/jitc-2024-010005.

Curcumin as a potential inhibitor of TGFβ3 computational insights for breast cancer therapy.

Alkhathami A, Alshahrani M, Alshehri S, Nasir N, Wahab S Sci Rep. 2025; 15(1):2871.

PMID: 39843618 PMC: 11754452. DOI: 10.1038/s41598-025-86289-0.

References

Glenisson W, Castronovo V, Waltregny D . Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta. 2007; 1773(10):1572-82. DOI: 10.1016/j.bbamcr.2007.05.016. View

Rifkin D . Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem. 2004; 280(9):7409-12. DOI: 10.1074/jbc.R400029200. View

Azad N, Zahnow C, Rudin C, Baylin S . The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013; 10(5):256-66. PMC: 3730253. DOI: 10.1038/nrclinonc.2013.42. View

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Cheng N, Bhowmick N, Chytil A, Gorksa A, Brown K, Muraoka R . Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005; 24(32):5053-68. PMC: 3074577. DOI: 10.1038/sj.onc.1208685. View

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

Roncarolo M, Levings M, Traversari C . Differentiation of T regulatory cells by immature dendritic cells. J Exp Med. 2001; 193(2):F5-9. PMC: 2193342. DOI: 10.1084/jem.193.2.f5. View

10.

Massague J, Gomis R . The logic of TGFbeta signaling. FEBS Lett. 2006; 580(12):2811-20. DOI: 10.1016/j.febslet.2006.04.033. View

11.

Feng X, Derynck R . Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005; 21:659-93. DOI: 10.1146/annurev.cellbio.21.022404.142018. View

12.

Amendt C, Schirmacher P, Weber H, Blessing M . Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene. 1998; 17(1):25-34. DOI: 10.1038/sj.onc.1202161. View

13.

Flavell R, Sanjabi S, Wrzesinski S, Licona-Limon P . The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010; 10(8):554-67. PMC: 3885992. DOI: 10.1038/nri2808. View

14.

Gorsch S, Memoli V, Stukel T, Gold L, Arrick B . Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992; 52(24):6949-52. View

15.

Laouar Y, Sutterwala F, Gorelik L, Flavell R . Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol. 2005; 6(6):600-7. DOI: 10.1038/ni1197. View

16.

Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y . Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol. 2007; 178(5):2763-9. DOI: 10.4049/jimmunol.178.5.2763. View

17.

Hills C, Willars G, Brunskill N . Proinsulin C-peptide antagonizes the profibrotic effects of TGF-beta1 via up-regulation of retinoic acid and HGF-related signaling pathways. Mol Endocrinol. 2010; 24(4):822-31. PMC: 5417534. DOI: 10.1210/me.2009-0391. View

18.

Li M, Flavell R . TGF-beta: a master of all T cell trades. Cell. 2008; 134(3):392-404. PMC: 3677783. DOI: 10.1016/j.cell.2008.07.025. View

19.

Dumont N, Bakin A, Arteaga C . Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem. 2002; 278(5):3275-85. DOI: 10.1074/jbc.M204623200. View

20.

Safina A, Vandette E, Bakin A . ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene. 2006; 26(17):2407-22. DOI: 10.1038/sj.onc.1210046. View